科研动态PubMed 摘要

营养对青光眼进展的影响:来自系统文献综述和荟萃分析的证据。

PubMed 学科轮询 · 2026-11-05

完整摘要 · 中文译文

主题:本系统综述与荟萃分析旨在确定营养干预是否对青光眼进展产生影响。所回答的临床问题是,与基线值相比,营养补充是否对青光眼进展的测量指标产生影响,即眼内压(IOP)、视野平均偏差(MD)、模式标准差(PSD)和视网膜神经纤维层(RNFL)厚度。 临床相关性:青光眼是一种慢性神经退行性视神经病变,是全球不可逆性失明的主要原因。青光眼的常规治疗是降低IOP以延缓青光眼的进展。然而,在IOP控制良好的患者中仍可见青光眼进展,提示需要寻找额外的治疗选择,包括营养因素、抗氧化剂、omega-3脂肪酸、维生素和营养保健品。 方法:对Cochrane对照试验中心注册库(CENTRAL)、PubMed、PubMed Central(PMC)和Google Scholar进行了从建库至2026年3月6日的全面检索。考虑纳入评估青光眼成人患者饮食、营养状况或营养补充并报告疾病进展结局的随机对照试验(RCT)和观察性研究。纳入研究的偏倚风险采用针对RCT的修订版Cochrane偏倚风险工具(RoB 2)和针对队列研究的纽卡斯尔-渥太华量表进行评估。 结果:定性综合纳入21项研究,共1,209名p 纳入的受试者,且有11项研究可进行荟萃分析。纳入的干预措施包括抗氧化剂、ω-3脂肪酸、维生素以及神经保护剂,如辅酶Q10、银杏叶提取物、胞磷胆碱和棕榈酰乙醇酰胺。荟萃分析发现,六个月时眼压(IOP)(平均差 - 2.42 mmHg,95% CI - 7.53 至 2.70)、平均偏差(MD)(2.23 dB,95% CI - 1.04 至 5.50)或视网膜神经纤维层(RNFL)厚度(- 16.00 µm,95% CI - 70.77 至 38.76)均无统计学显著变化,但图案标准差(PSD)有显著降低(- 0.33 dB,95% CI - 0.47 至 - 0.19)。 结论:现有证据表明,营养干预在短期内不会显著影响青光眼进展的主要指标;基于三项队列研究得出的PSD小幅降低不应被解读为具有临床意义的神经保护效应。鉴于 underlying evidence 的证据确定性为低至中等,营养补充剂可被视为常规治疗的潜在辅助手段,但支持其常规临床应用的证据仍不充分;营养补充剂对青光眼的长期影响需要通过大型、长期随机对照试验(RCT)来确定。

完整摘要 · 英文原文

TOPIC: This systematic review and meta-analysis aims to determine if nutritional interventions have an impact on glaucoma progression. The clinical question being answered is whether nutritional supplementation compared to baseline values has an impact on measures of glaucoma progression, i.e., intraocular pressure (IOP), visual field mean deviation (MD), pattern standard deviation (PSD), and retinal nerve fiber layer (RNFL) thickness. CLINICAL RELEVANCE: Glaucoma is a chronic neurodegenerative optic neuropathy and is a major cause of irreversible blindness worldwide. The conventional treatment for glaucoma is to reduce IOP to slow the progression of glaucoma. However, progression of glaucoma is seen in patients with well-controlled IOP levels, suggesting that there is a need to look for additional therapeutic options, including nutritional factors, antioxidants, omega-3 fatty acids, vitamins, and nutraceuticals. METHODS: A comprehensive search of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, PubMed Central (PMC), and Google Scholar was undertaken from date of inception to 6 March, 2026. Randomized controlled trials (RCTs) and observational studies evaluating the diet, nutritional status, or nutritional supplementation in adults with glaucoma and reporting outcomes on the progression of the disease were considered for inclusion. Risk of bias in the included studies was assessed with the revised Cochrane Risk of Bias tool (RoB 2) for RCTs and the Newcastle-Ottawa Scale for cohort studies. RESULTS: Qualitative synthesis included 21 studies with 1,209 participants, and 11 studies were available for meta-analysis. Antioxidants, omega-3 fatty acids, vitamins, and neuroprotective agents such as coenzyme Q10, ginkgo biloba extract, citicoline, and palmitoylethanolamide were included. Meta-analysis found no statistically significant change at six months in IOP (mean difference - 2.42 mmHg, 95% CI - 7.53 to 2.70), MD (2.23 dB, 95% CI - 1.04 to 5.50), or RNFL thickness (- 16.00 µm, 95% CI - 70.77 to 38.76), although there was a significant decrease in PSD (- 0.33 dB, 95% CI - 0.47 to - 0.19). CONCLUSION: The current evidence suggests that nutritional interventions do not significantly affect major indicators of glaucoma progression in the short term; the small PSD reduction, based on three cohort studies, should not be interpreted as a clinically meaningful neuroprotective effect. Given the low-to-moderate certainty of the underlying evidence, nutritional supplements may be considered as a potential adjunct to conventional treatment, though evidence supporting their routine clinical use remains insufficient; the long-term effects of nutritional supplements on glaucoma need to be determined through large, long-term RCTs.

English
The impact of nutrition on glaucoma progression: evidence from systematic literature review and meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界